Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $1.87 in the prior trading day, Outlook Therapeutics Inc (NASDAQ: OTLK) closed at $1.71, down -8.56%. In other words, the price has decreased by -$8.56 from its previous closing price. On the day, 0.7 million shares were traded.
Ratios:
Our goal is to gain a better understanding of OTLK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.32.
On March 27, 2024, BTIG Research Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50. Chardan Capital Markets Upgraded its Neutral to Buy on February 15, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 26 ’24 when KENYON LAWRENCE A bought 5,000 shares for $5.69 per share. The transaction valued at 28,446 led to the insider holds 5,946 shares of the business.
Haddadin Yezan Munther bought 1,882 shares of OTLK for $22,242 on Mar 28 ’24. The Director now owns 5,049 shares after completing the transaction at $11.82 per share. On Mar 07 ’24, another insider, Evanson Jeff, who serves as the CHIEF COMMERCIAL OFFICER of the company, bought 62,484 shares for $0.42 each. As a result, the insider paid 26,243 and bolstered with 808,459 shares of the company.
Stock Price History:
Over the past 52 weeks, OTLK has reached a high of $12.85, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is -7.47%, while the 200-Day Moving Average is calculated to be -69.05%.
Shares Statistics:
A total of 24.91M shares are outstanding, with a floating share count of 23.59M. Insiders hold about 26.33% of the company’s shares, while institutions hold 14.44% stake in the company.
Earnings Estimates
Investors are keenly observing as 2.0 analysts analyze and rate the current performance of Outlook Therapeutics Inc (OTLK) in the stock market.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.33 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.4 and -$2.33 for the fiscal current year, implying an average EPS of -$1.87. EPS for the following year is -$1.05, with 2.0 analysts recommending between -$0.95 and -$1.16.
Revenue Estimates
Based on 3 analysts’ estimates, the company’s revenue will be $44.18M in the next fiscal year. The high estimate is $50.95M and the low estimate is $33.6M.
